Literature DB >> 35535090

Hepatogenous Diabetes - A Report from Central India.

Praveen Vasepalli1, Mohd T Noor1, Bhagwan S Thakur1.   

Abstract

Background/
Objectives: Cirrhosis of liver is associated with loss of liver function, portal hypertension, and pancreatic β-cell dysfunction leading to hepatogenous diabetes (HD). Often HD is an underestimated and understudied problem, particularly in the Indian subcontinent, where the prevalence of both Chronic liver disease (CLD) and diabetes is high. Hence this study was planned to highlight the prevalence of HD and its association with the severity of cirrhosis.
Methods: A total of 121 cirrhotic patients without a history of diabetes were included in this prospective cross-sectional study. Seventy five g oral glucose tolerance test (OGTT) was done in all patients. Fasting serum insulin levels were done to calculate insulin resistance (IR) using homeostatic model assessment-insulin resistance (HOMA-IR). Upper gastrointestinal endoscopy was done to detect varices. Patients were divided into HD group and non-HD group for comparison of results.
Results: HD was seen in 52 (42.98%) patients; among them, 63.4% did not show evidence of HD by fasting plasma glucose (FPG) levels. Impaired glucose tolerance (IGT) was seen in 58 (47.93%) patients. Compared with the non-HD group, the HD group had significantly higher model for end-stage liver disease (MELD) score (P = 0.038), HOMA-IR (P < 0.001), incidence of large varices (P < 0.001) and variceal bleeding (P < 0.001). A statistically significant association was noted between HD and Hepatocellular carcinoma (HCC) (P < 0.001).
Conclusion: Patients with cirrhosis had a high prevalence of IGT, IR, and HD. The presence of HD is well associated with the severity of cirrhosis in the form of higher MELD score (>15), CTP score (>10), higher bilirubin levels, large varices, bleeding varices, and HCC. FPG levels and glycated hemoglobin (HbA1c) cannot be relied upon, and OGTT aids in the unmasking of HD in these patients.
© 2021 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  120-min PG, 120 min plasma glucose; AASLD, American association for the study of liver diseases; ADA, American diabetic association; CLD, chronic liver disease; CTP score, Child-Turcotte-Pugh score; DM, diabetes mellitus; FPG, fasting plasma glucose; HCC, hepatocellular carcinoma; HD, hepatogenous diabetes; HOMA-IR, homeostatic model assessment-insulin resistance; HVPG, hepatic venous pressure gradient; HbA1c, glycated hemoglobin; IGF, insulin-like growth factor; IGT, impaired glucose tolerance; IR, insulin resistance; MELD score, model for end-stage liver disease; OGTT, oral glucose tolerance test; SPSS, statistical software for social sciences; T2DM, type 2 diabetes mellitus; chronic liver disease; hepatogenous diabetes; impaired glucose tolerance; insulin resistance; variceal bleeding

Year:  2021        PMID: 35535090      PMCID: PMC9077220          DOI: 10.1016/j.jceh.2021.08.018

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  34 in total

1.  Insulin resistance and chronic liver disease.

Authors:  Takumi Kawaguchi; Eitaro Taniguchi; Minoru Itou; Masahiro Sakata; Shuji Sumie; Michio Sata
Journal:  World J Hepatol       Date:  2011-05-27

2.  The current state of diabetes mellitus in India.

Authors:  Seema Abhijeet Kaveeshwar; Jon Cornwall
Journal:  Australas Med J       Date:  2014-01-31

3.  Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis.

Authors:  Tsutomu Nishida; Shingo Tsuji; Masahiko Tsujii; Shoko Arimitsu; Yoshimichi Haruna; Eiichi Imano; Masaaki Suzuki; Tsutomu Kanda; Sunao Kawano; Naoki Hiramatsu; Norio Hayashi; Masatsugu Hori
Journal:  Am J Gastroenterol       Date:  2006-01       Impact factor: 10.864

4.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

5.  Hepatogenous diabetes: Is it a neglected condition in chronic liver disease?

Authors:  Diego García-Compeán; José Alberto González-González; Fernando Javier Lavalle-González; Emmanuel Irineo González-Moreno; Jesús Zacarías Villarreal-Pérez; Héctor Jesús Maldonado-Garza
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

6.  Hepatogenous diabetes in cirrhosis is related to portal pressure and variceal hemorrhage.

Authors:  Hyo Keun Jeon; Moon Young Kim; Soon Koo Baik; Hong Jun Park; Hoon Choi; So Yeon Park; Bo Ra Kim; Jin Heon Hong; Ki Won Jo; Seung Yong Shin; Jung Min Kim; Jae Woo Kim; Hyun Soo Kim; Sang Ok Kwon; Young Ju Kim; Seung Hwan Cha; Dong Joon Kim; Ki Tae Suk; Gab Jin Cheon; Young Don Kim; Dae Hee Choi; Sung Joon Lee
Journal:  Dig Dis Sci       Date:  2013-08-04       Impact factor: 3.199

7.  Impacts of TCF7L2 gene polymorphisms on the susceptibility of hepatogenous diabetes and hepatocellular carcinoma in cirrhotic patients.

Authors:  Qi Ling; Fengqin Dong; Lei Geng; Zhikun Liu; Haiyang Xie; Xiao Xu; Shusen Zheng
Journal:  Gene       Date:  2013-04-02       Impact factor: 3.688

8.  Glucose intolerance in liver cirrhosis: role of hepatic and non-hepatic influences.

Authors:  M J Müller; M Pirlich; H J Balks; O Selberg
Journal:  Eur J Clin Chem Clin Biochem       Date:  1994-10

9.  The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies.

Authors:  Wan-Shui Yang; Puthiery Va; Freddie Bray; Shan Gao; Jing Gao; Hong-Lan Li; Yong-Bing Xiang
Journal:  PLoS One       Date:  2011-12-21       Impact factor: 3.240

10.  Insulin resistance in euglycemic cirrhosis.

Authors:  Amitava Goswami; Narendra Bhargava; Sunil Dadhich; Ganaraj Kulamarva
Journal:  Ann Gastroenterol       Date:  2014
View more
  1 in total

Review 1.  Hepatogenous diabetes: Knowledge, evidence, and skepticism.

Authors:  Ramesh Kumar; Diego García-Compeán; Tanmoy Maji
Journal:  World J Hepatol       Date:  2022-07-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.